Daily Endocrinology Research Analysis
Analyzed 103 papers and selected 3 impactful papers.
Summary
Across endocrinology, three studies stand out: a meta-analysis of 22 randomized trials shows tirzepatide significantly reduces major adverse cardiovascular events and all-cause mortality. A Nature Metabolism study identifies the nerve perineurium as a leptin-sensitive interface integrating afferent signaling with sympathetic outflow to defend against obesity. A multicenter randomized trial finds intermittent, as‑needed metformin after gestational diabetes is non-inferior to continuous therapy for diabetes prevention over 3 years.
Research Themes
- Cardiometabolic therapeutics that improve hard outcomes
- Neuro-adipose circuits and leptin-mediated energy homeostasis
- Postpartum diabetes prevention strategies in high-risk women
Selected Articles
1. Tirzepatide, cardiovascular outcomes and mortality in obesity and diabetes: a systematic review and meta-analysis.
In a meta-analysis of 22 RCTs (n=29,023), tirzepatide reduced major adverse cardiovascular events (OR 0.87) and all-cause mortality (OR 0.84), with trial sequential analysis supporting definitive conclusions. A dose–response relationship was observed, while effects on individual MACE components and heart failure hospitalizations were not significant.
Impact: This synthesis provides high-level evidence that tirzepatide confers cardiovascular and survival benefits in people with obesity or T2D, informing therapeutic choices and guideline development.
Clinical Implications: For adults with T2D or obesity, tirzepatide can be prioritized when cardiovascular risk reduction is a goal, with expectations of MACE and mortality reduction; however, clinicians should not assume benefit for individual MACE components or heart failure hospitalizations.
Key Findings
- Across 22 RCTs (n=29,023), tirzepatide reduced MACE (OR 0.87, 95% CI 0.79–0.94; high certainty).
- Dose–response: 2.8% lower odds of MACE per 1 mg increase in tirzepatide dose.
- All-cause mortality was reduced (OR 0.84, 95% CI 0.75–0.93); individual MACE components and heart failure hospitalizations showed no significant differences.
- Trial sequential analysis indicated the information size was sufficient for definitive conclusions.
Methodological Strengths
- Meta-analysis of randomized controlled trials with low overall risk of bias and trial sequential analysis.
- Dose–response assessment supports biological plausibility and robustness.
Limitations
- No significant effect on individual MACE components or heart failure hospitalizations.
- Included trials had minimum follow-up of 24 weeks; longer-term cardiovascular safety signals by component remain uncertain.
Future Directions: Prospective trials powered for individual MACE components and heart failure outcomes, with longer follow-up, and mechanistic work to explain dose–response across cardio-renal-metabolic pathways.
AIMS: To assess the effect of tirzepatide, a glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonist, on cardiovascular outcomes and mortality in subjects with overweight/obesity, or type 2 diabetes mellitus (T2DM). METHODS: We searched MEDLINE, Embase and CENTRAL up to January 14, 2026, selecting randomized controlled trials studying tirzepatide in adults with T2DM or overweight/obesity with a minimum follow-up of 24 weeks. We independently extracted data and assessed risk of bias and quality of evidence. We conducted meta-analysis using a fixed-effects model. Trial sequential analysis (TSA) was employed to assess if current information support definitive conclusions. RESULTS: We included 22 trials encompassing 29,023 participants. Overall risk of bias was low. Tirzepatide was associated with a reduction in MACE (OR 0.87, 95% CI 0.79-0.94; high certainty); TSA estimated that sample size was sufficient for definitive conclusions. A dose-response association was observed, with 2.8% lower odds of MACE for every 1 mg increase in tirzepatide dose. Tirzepatide was associated with a reduction in all-cause mortality (OR 0.84, 95% CI 0.75-0.93), however no association was observed for individual components of MACE or heart failure hospitalizations. CONCLUSIONS: Tirzepatide is associated with a significant reduction in MACE in subjects with T2DM or overweight/obesity.
2. The perineurium integrates leptin with its sympathetic outflow to protect against obesity.
This study identifies the nerve perineurium as a leptin-responsive interface that integrates afferent leptin signaling with sympathetic efferent output to adipose tissues. Enriched expression of Lepr within the perineurium supports a mechanistic role for this barrier tissue in defending against obesity.
Impact: It uncovers a previously unappreciated peripheral neural structure—perineurium—as a key site integrating leptin signaling with autonomic control of adipose tissue, reframing targets for anti-obesity interventions.
Clinical Implications: While preclinical, the work suggests neuromodulatory or barrier-targeted strategies at the perineurium could modulate adipose sympathetic tone and energy balance, informing future obesity therapeutics.
Key Findings
- The perineurium was identified as a leptin-responsive interface linking afferent leptin signaling with sympathetic efferent innervation of white and brown adipose tissue.
- Enriched expression of leptin receptor (Lepr) in the perineurium supports its mechanistic role in energy homeostasis.
- Findings suggest a peripheral regulatory node for balancing leptin’s afferent action and sympathetic outflow, with implications for obesity defense.
Methodological Strengths
- Mechanistic identification of a specific peripheral neural structure implicated in energy homeostasis.
- Integration of neurobiology and metabolic physiology to propose a testable framework.
Limitations
- Preclinical mechanistic work; absence of human interventional data limits immediate translation.
- Abstracted details on downstream functional manipulations are limited in the provided text.
Future Directions: Validate perineurial leptin signaling in human tissues, define molecular mediators, and test whether targeted modulation alters adipose sympathetic tone and body weight in vivo.
The regulatory mechanism of leptin's afferent action in the brain is contingent upon the efferent sympathetic innervation of white and brown adipose tissues. Nonetheless, the peripheral regulation governing the afferent-efferent balance remains ambiguous. Here we show the enriched expression of both leptin receptor (Lepr) and β
3. The efficacy of intermittent metformin plus lifestyle intervention for diabetes prevention in women with prediabetes and prior gestational diabetes: a randomized clinical, non-inferiority trial.
In 376 postpartum women with prediabetes after GDM, intermittent as‑needed metformin plus lifestyle intervention was non-inferior to continuous metformin over 3 years for preventing T2D (11.5% vs 11.1%; absolute difference 0.4%, 95% CI −6.5 to 7.4). Secondary outcomes did not differ, while metformin-related vitamin B deficiency was more frequent with continuous therapy.
Impact: This pragmatic non-inferiority RCT supports a flexible, exposure-sparing metformin strategy for diabetes prevention after GDM, potentially reducing adverse effects without sacrificing efficacy.
Clinical Implications: For postpartum women with prediabetes after GDM, clinicians may consider intermittent, as-needed metformin alongside lifestyle counseling to minimize drug exposure and vitamin B deficiency risk while maintaining preventive efficacy.
Key Findings
- Intermittent metformin was non-inferior to continuous metformin for 3-year T2D incidence (11.5% vs 11.1%; absolute difference 0.4%, 95% CI −6.5 to 7.4).
- No significant differences in secondary outcomes (prediabetes remission, anthropometrics, glycemia).
- Continuous therapy showed a higher rate of metformin-related vitamin B deficiency.
Methodological Strengths
- Multicenter randomized non-inferiority design with 3-year follow-up and intention-to-treat analysis.
- Clinically pragmatic strategy comparing continuous versus as-needed dosing layered on lifestyle intervention.
Limitations
- Open-label design with a relatively wide non-inferiority margin (10 percentage points).
- Conducted in China; generalizability to other populations and healthcare settings requires confirmation.
Future Directions: Confirm equivalence or non-inferiority with narrower margins, larger event counts, diverse populations, and evaluate long-term safety including micronutrient status.
BACKGROUND: In women with prediabetes after prior gestational diabetes mellitus (GDM), whether intermittent metformin treatment as needed is as effective as continuous use in preventing type 2 diabetes mellitus (T2DM) is unknown. We aimed to test whether an intermittent metformin treatment is non-inferior to continuous metformin strategy for prevention of T2DM in women with prediabetes after GDM. METHODS: A randomized, open-label, non-inferiority trial was conducted at three centers in China. Women aged 18-45 years with prior GDM and prediabetes at 4-12 weeks postpartum were randomly assigned to receive lifestyle intervention plus intermittent or continuous metformin treatment. In the continuous group, participants were initially treated with lifestyle intervention and metformin was initiated when lifestyle intervention alone failed to maintain euglycemia and continued without interruption throughout the trial. In the intermittent group, participants were initially treated with lifestyle intervention and metformin was added when they failed to maintain euglycemia and was discontinued if the glycemic status returned to normal. The primary outcome was the difference in incidences of newly diagnosed diabetes between the two groups during the 3-year follow-up, compared against a non-inferiority margin of 10-percentage-point by following the intention-to-treat principle. Secondary outcomes included the percentage of prediabetes remission, changes from baseline in body weight, body mass index, waist circumference, fasting plasma glucose, 2-h plasma glucose, and hemoglobin A1c. RESULTS: Among the 376 women randomized, 11.5% of women in the intermittent group and 11.1% in the continuous group developed newly diagnosed T2DM after three years (absolute risk difference 0.4% points [95% CI -6.5 to 7.4], meeting criteria for non-inferiority). None of the secondary outcomes were significantly different between the two groups. Women in the continuous group experienced higher rate of metformin-related vitamin B CONCLUSIONS: In postpartum women with prediabetes after GDM, a strategy of intermittent metformin as needed plus lifestyle intervention met the pre-specified 10-percentage-point non-inferiority margin for 3-year T2DM incidence compared with continuous metformin plus lifestyle intervention. The equivalence of the two metformin strategies needs to be confirmed in further trials with a narrower margin and a larger event count. TRIAL REGISTRATION: The study was registered in the Chinese Clinical Trial Registry (ChiCTR-IOR-17012770).